Last 74.30 INR
Change Today -0.45 / -0.60%
Volume 557.5K
As of 5:28 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

orchid chemicals & pharma (OCP) Snapshot

Open
74.25
Previous Close
74.75
Day High
76.35
Day Low
74.00
52 Week High
07/15/14 - 85.45
52 Week Low
08/6/13 - 34.80
Market Cap
5.2B
Average Volume 10 Days
2.9M
EPS TTM
--
Shares Outstanding
70.5M
EX-Date
09/13/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORCHID CHEMICALS & PHARMA (OCP)

Related News

No related news articles were found.

orchid chemicals & pharma (OCP) Related Businessweek News

No Related Businessweek News Found

orchid chemicals & pharma (OCP) Details

Orchid Chemicals & Pharmaceuticals Limited, an integrated pharmaceutical company, is engaged in the research, development, manufacture, marketing, and export of active pharmaceutical ingredients (APIs) and finished dosage forms worldwide. Its API product portfolio includes oral cephalosporins, injectable cephalosporins, carbapenems, non-antibiotics, penicillins, and veterinary products. The company also offers anti-infectives, anti-inflammatory, central nervous system, cardio vascular system, nutraceutical, other oral and sterile products, anti-diabetic formulations, and neuropsychiatry system formulations, as well as nutritional supplements. In addition, it provides new drug discovery, novel drug delivery systems, and contract research and manufacturing services. Orchid Chemicals & Pharmaceuticals Limited was founded in 1992 and is headquartered in Chennai, India.

4,455 Employees
Last Reported Date: 08/27/12
Founded in 1992

orchid chemicals & pharma (OCP) Top Compensated Officers

Managing Director, Executive Director, Chairm...
Total Annual Compensation: 74.2M
Compensation as of Fiscal Year 2013.

orchid chemicals & pharma (OCP) Key Developments

Orchid Chemicals & Pharmaceuticals Limited, Board Meeting, Jul 14, 2014

Orchid Chemicals & Pharmaceuticals Limited, Board Meeting, Jul 14, 2014. Agenda: To approve the issue of shares to promoters on a preferential basis pursuant to the conditions of CDR package sanctioned to the company by Corporate Debt Restructuring Cell.

Orchid Chemicals & Pharmaceuticals Limited Receives US FDA Approval for Eszopiclone Tablets ANDA

Orchid Chemicals & Pharmaceuticals Limited announced that it has Received approval from the US FDA for its ANDA (Abbreviated New Drug Application) for Eszopiclone Tablets, 1 mg, 2 mg, and 3 mg strengths.

Orchid Chemicals & Pharmaceuticals Limited Announces Management and Executive Changes

Orchid Chemicals & Pharmaceuticals Limited informed that in the meeting of the board held on May 12, 2014, Shri. K N Venkatasubramanian, (non-executive, independent director) has been designated as the chairman of the company and consequent to this, Shri K. Raghavendra Rao has been re-designated as the managing director of the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCP:IN 74.30 INR -0.45

OCP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CF Industries Holdings Inc $252.61 USD -1.95
Phosagro OAO 1,315 RUB -4.20
Potash Corp of Saskatchewan Inc C$39.42 CAD +0.50
Saudi Arabian Mining Co SR38.39 SAR +0.75
Mosaic Co/The $47.10 USD -0.24
View Industry Companies
 

Industry Analysis

OCP

Industry Average

Valuation OCP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORCHID CHEMICALS & PHARMA, please visit www.orchidpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.